SageMedic Corp.
- Diagnostics
- Patient advocacy
SageMedic Corp.'s breakthrough technology overcomes the limitations of genomic testing to identify the most effective treatment for millions of cancer patients. We are the only company that can create hundreds of native 3D microtumors from a patient's live cancer biopsy overnight in our lab, expose those microtumors to a panel of drugs, and identify the most effective therapy in just a few days.
More importantly, the SAGE Oncotest; is now CMS accredited so that SAGE has already been able to start a soft launch for selected patients. This enables us to perfectly adjust to the needs of both the oncologists and patients, understand the willingness-to-pay, and generate real world evidence that can further inform clinical trials design that will be coupled with health economic analyses. We have modelled our financial projections after Genomic Health, who became a market leader in predicting the risk for breast cancer tumor recurrence, and has been acquired by Exact Sciences for $2.8 billion.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}